Drug Trial Radar · NCT06769633
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
Last checked: Nov 20, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Jan 2, 2025
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- ItalfarmacoIndustry
- Sponsor type
- Industry
- Collaborators
- Fortrea
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 2 years, up to 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in younger DMD Patients. * Planned screening duration: approximately 4 weeks * Planned Core Treatment duration: approximately 48 weeks * Planned Extension Treatment duration: approximately 96 weeks * Planned Follow Up duration: approximately 4 weeks (± 7 days) * Total duration of study participation: up to 151 weeks (ie, 37-38 months)
Conditions
- Duchenne Muscular Dystrophy
Interventions
Givinostat HydrochlorideDrug
Cohort 1 - from 4 to 6 years old
Givinostat Hydrochloride - Cohort 2Drug
Cohort 2 - from 2 to 4 years old
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Phase: Cohort 1 - Change from baseline of the pharmacokinetic (PK) parameter Area under the concentration-time curve from dosing (time 0) to time t at steady state (AUC0-T,ss).Time frame: Baseline up to week 48
- Core Phase: Cohort 1 - Change from baseline of the pharmacokinetic (PK) parameter maximum plasma concentration at steady state (Cmax,ss).Time frame: Baseline up to week 48
- Core Phase: Cohort 1 - Change from baseline of the pharmacokinetic (PK) parameter elimination half-life (t1/2) assessed after at least 7 days of dosing.Time frame: Baseline up to week 48
- Core Phase: Cohort 2 - Change from baseline of the pharmacokinetic (PK) parameter Area under the concentration-time curve from dosing (time 0) to time t at steady state (AUC0-T,ss).Time frame: Baseline up to week 48
- Core Phase: Cohort 2 - Change from baseline of the pharmacokinetic (PK) parameter maximum plasma concentration at steady state (Cmax,ss).Time frame: Baseline up to week 48
- Core Phase: Cohort 2 - Change from baseline of the pharmacokinetic (PK) parameter elimination half-life (t1/2) assessed after at least 7 days of dosingTime frame: Baseline up to week 48
- Extension Phase: Type, incidence, and severity of treatment-emergent adverse eventsTime frame: postbaseline up to Week 144
- Extension Phase: Proportion of patients experiencing treatment-emergent adverse eventsTime frame: postbaseline up to Week 144
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Queen Fabiola Children's University Hospital HUDERF
Brussels, Belgium · Recruiting
Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - NeuroMuscolar Omnicenter
Milan, Italy · Recruiting
Ospedale Pediatrico Bambino Gesù
Roma, Italy · Recruiting
Policlinico Universitario Agostino Gemelli - Università Cattolica del Sacro Cuore
Roma, Italy · Recruiting
Leids Universitair Medisch Centrum (LUMC)
Leiden, Netherlands · Recruiting
Leeds Teaching Hospital NHS Trust
Leeds, England, United Kingdom · Not yet recruiting
Great Ormond Street Hospital - GOSH
London, England, United Kingdom · Not yet recruiting
Newcastle upon Tyne Hospitals NHS Foundation Trust - Newcastle University
Newcastle upon Tyne, England, United Kingdom · Recruiting
Oxford University Hospitals NHS Foundation Trust
Oxford, England, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.